Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.
Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55%
Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III LUCIDITY trial of avexitide met its primary endpoint, reducing the composite rate of clinically significant hypoglycemic events by 55% versus placebo in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
Amylyx Pharmaceuticals, Inc. Common Stock Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 55 | $765 | $1,117.05 | $352.05 | 46.02% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 90 | $340.2 | $2,126.7 | $1,786.5 | 525.13% |
| BG Bart Gancher Intech Investment Management LLC | 19,775 | $197,700.79 | $448,299.25 | $250,598.46 | 126.76% |
| JM John Malone Amundi | 12,895 | $179,240.5 | $292,329.65 | $113,089.15 | 63.09% |
 Joseph Castro Nuveen LLC | 330,521 | $3.61M | $7.49M | $3.88M | 107.44% |
Amylyx Pharmaceuticals, Inc. Common Stock Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Andrew S. Fein HC Wainwright & Co. | 5,613.83 | $197,101.73 | $216,694.02 | $19,592.29 | 9.94% |
 Joel Beatty Baird | 8,947.99 | $345,392.28 | $345,392.28 | - | - |
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Amylyx Pharmaceuticals, Inc. Common Stock ever had a stock split?
Amylyx Pharmaceuticals, Inc. Common Stock Profile
| Biotechnology Industry | Healthcare Sector | Joshua Cohen CEO | NASDAQ (NGS) Exchange | 03237H101 CUSIP |
| US Country | 136 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Amylyx Pharmaceuticals, Inc., established in 2013 and based in Cambridge, Massachusetts, operates as a commercial-stage biotechnology company specialized in the discovery and development of treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company’s focus is on delivering innovative therapies that can potentially improve the quality of life for patients facing debilitating conditions. Amylyx is dedicated to scientific innovations and has made notable progress in the field of neurodegenerative disease treatment through its rigorous research and development activities.
Products and Services
- RELYVRIO
- AMX0114
An innovative therapy developed for the treatment of amyotrophic lateral sclerosis (ALS) in adults within the United States. RELYVRIO is a dual UPR-Bax apoptosis inhibitor, composed of two active ingredients: sodium phenylbutyrate and taurursodiol. This medication represents a critical advancement in the treatment options available for patients suffering from ALS, offering them hope and potentially improving their quality of life. Outside of the United States, RELYVRIO is marketed as ALBRIOZA, providing the same innovative treatment to ALS patients in Canada.
Currently in the development stage, AMX0114 is another promising therapeutic candidate being explored by Amylyx Pharmaceuticals for its potential application in treating a broader range of neurodegenerative diseases beyond ALS. This expansion of their product pipeline signifies the company's commitment to leveraging their scientific expertise and understanding of neurodegeneration to address the unmet needs of individuals affected by various forms of neurodegenerative diseases.
